Summary of findings: bevacizumab vs ranibizumab
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
- Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes onlyRR 1 [0.98, 1.02]8 studies · 3144 participantsHigh